Oncotarget

Research Papers:

Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis

Valentina Cocciolone _, Katia Cannita, Maria Letizia Calandrella, Enrico Ricevuto, Paola Lanfiuti Baldi, Tina Sidoni, Azzurra Irelli, Stefania Paradisi, Laura Pizzorno, Valter Resta, Alberto Bafile, Edoardo Alesse, Alessandra Tessitore and Corrado Ficorella

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:72031-72043. https://doi.org/10.18632/oncotarget.18526

Metrics: PDF 530 views  |   HTML 1482 views  |   ?  


Abstract

Valentina Cocciolone1,2, Katia Cannita1, Maria Letizia Calandrella1, Enrico Ricevuto2,3, Paola Lanfiuti Baldi1, Tina Sidoni1, Azzurra Irelli1, Stefania Paradisi1, Laura Pizzorno4, Valter Resta4, Alberto Bafile4, Edoardo Alesse2, Alessandra Tessitore2 and Corrado Ficorella1,2

1Medical Oncology, S. Salvatore Hospital, University of L'Aquila, Via Vetoio, 67100 L’Aquila, Italy

2Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Via Vetoio, 67100 L’Aquila, Italy

3Oncology Network ASL1 Abruzzo, UOSD Oncology Territorial Care, S. Salvatore Hospital, University of L'Aquila, Via Vetoio, 67100 L’Aquila, Italy

4Breast Unit, S. Salvatore Hospital, L’Aquila, Via Vetoio, 67100 L’Aquila, Italy

Correspondence to:

Valentina Cocciolone, email: vale.cocciolone@tiscali.it

Keywords: clinicopathological prognostic factors, early breast cancer, clinical practice, survival, 20-year follow-up

Received: November 08, 2016     Accepted: June 02, 2017     Published: June 16, 2017

ABSTRACT

Background: To quantify the effect of traditional prognostic factors [nodal status, estrogen-receptor (ER), progesterone-receptor (PR), human epidermal growth factor receptor 2 (HER2)] on long-term outcome of patients with early breast cancer (EBC), treated in clinical practice over a period of about twenty years.

Results: 1198 consecutive patients were identified. Median DFS (disease-free survival): ER+/PR±/HER2−, 165 months (mo) if node-negative (N0) and 114mo if node-positive (N+) (p < 0.001); triple-negative (TN), 109mo if N0 and 65mo if N+ (p 0.144); ER+/PR±/HER2+ in patients not-treated with adjuvant trastuzumab (T−), not reached if N0 and 114mo if N+ (p 0.297); ER+/PR±/HER2+ in patients treated with trastuzumab (T+), 95mo if N0 and 85mo if N+ (p 0.615); ER−/PR−/HER2+ T−, not reached if N0 and 26mo if N+ (p 0.279); ER−/PR−/HER2+ T+, not reached if N0 and 66mo if N+ (p 0.014). Median OS (overall survival): ER+/ PR±/HER2−, 166mo if N0 and 144mo if N+ (p 0.028); TN, 158mo if N0 and 96mo if N+ (p 0.384); ER+/PR±/HER2+ T−, not reached if N0 and 157mo if N+ (p 0.475), ER+/PR±/HER2+ T+, not reached if N0 and 106mo if N+ (p 0.436); ER−/PR−/HER2+ T−, not reached if N0 and 34mo if N+ (p 0.273); ER−/PR−/HER2+ T+, not reached neither if N0 nor if N+ (p 0.094).

Materials and Methods: Disease-free survival (DFS) and overall survival (OS) were evaluated according to tumor characteristics, based on information retrospectively retrieved from patients’ medical records.

Conclusions: Pathological tumor characteristics and nodal status still represent useful tools in treatment selection and follow-up decision making of EBC patients in clinical practice.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18526